A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia

Sites Open (GLOBAL): 211

Sites Open (UK): 120

Randomised patients (GLOBAL): 1072

Randomised COVID-19 patients (GLOBAL): 558

Randomised COVID-19 patients (UK): 369

Individual site recruitment is available here. Last updated 02/06/2020, 12:15

What is this study about?

REMAP-CAP is an international (15 countries) adaptive platform trial that was specifically designed to be employed in a pandemic to evaluate multiple interventions simultaneously in critically ill patients.

The trial is modular so that new domains (groups of similar treatment options) can be added over time.

Current domains include

  • Antivirals (four interventions: (1) no antiviral; (2) lopinavir/ritonavir; (3) hydroxychloroquine; (4) lopinavir/ritonavir and hydroxychloroquine combination)
  • immunomodulation (five interventions: (1) no immune modulation (2) interferon beta 1a (3) interleukin 1 receptor antagonist [anakinra] (4 and 5) interleukin 6 inhibition [tocilizumab and sarilumab])
  • Corticosteroids (three interventions: (1) no steroids; (2) steroids for 7 days (3) steroids if shock present)
  • Immunoglobulin therapy (two interventions: (1) no immunoglobulin; (2) convalescent plasma)
  • Therapeutic anticoagulation (two interventions: (1) local standard venous thromboprophylaxis (2) therapeutic anticoagulation with intravenous unfractionated heparin or subcutaneous low molecular weight heparin)

Further informtion can be found on the global REMAP-CAP website

Information for sites

Information is available for participating sites on set-up, randomisation, pharmacy arrangements and FAQs.

Chief Medical Officers' letter of support

REMAP-CAP has been named as one of the three national randomised trials in COVID-19. Please find the letter of support encouraging participation of all hospitals into these studies.


REMAP-CAP is registered at NCT02735707
EudraCT number: 2015-002340-14

Funding and support

European Commission FP7: Platform foR European Preparedness Against (Re-)emerging Epidemics
Prioritised by the National Institute For Health Research as a COVID19 study

Copyright © 2020 ICNARC